4.8 Article

Colorectal Tumor Microenvironment-Activated Bio-Decomposable and Metabolizable Cu2O@CaCO3Nanocomposites for Synergistic Oncotherapy

Journal

ADVANCED MATERIALS
Volume 32, Issue 43, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.202004647

Keywords

bio-decomposition; colorectal tumor microenvironment; Cu2O@CaCO3; metabolism; synergistic oncotherapy

Funding

  1. Chinese Government [2017YFE0132300]
  2. Australian Government [2017YFE0132300]
  3. National Natural Science Foundation of China [NSFC 51929201, 51672268, 51720105015, 51972138, 51872263, 51828202]
  4. Science and Technology Development Planning Project of Jilin Province [20190201232JC]
  5. CAS-Croucher Funding Scheme for Joint Laboratories [CAS18204]
  6. Guangdong Natural Science Foundation [2019A1515012214]

Ask authors/readers for more resources

Rational design of tumor microenvironment (TME)-activated nanocomposites provides an innovative strategy to construct responsive oncotherapy. In colorectal cancer (CRC), the specific physiological features are the overexpressed endogenous H2S and slightly acidic microenvironment. Here, a core-shell Cu2O@CaCO(3)nanostructure for CRC turn-on therapy is reported. With CaCO(3)responsive to pH decomposition and Cu2O responsive to H2S sulfuration, Cu2O@CaCO(3)can be triggered on into the therapeutic mode by the colorectal TME. When the CaCO(3)shell decomposes and releases calcium in acidic colorectal TME, the loss of protection from the CaCO(3)shell exposes the Cu2O core to be sulfuretted by H2S to form metabolizable Cu(31)S(16)nanocrystals that gain remarkably strong near-infrared absorption. After modifying hyaluronic acid, Cu2O@CaCO(3)can achieve synergistic CRC-targeted and TME-triggered photothermal/photodynamic/chemodynamic/calcium-overload-mediated therapy. Moreover, it is found that the generation of hyperthermia and oxidative stress from Cu2O@CaCO(3)nanocomposites can efficiently reprogram the macrophages from the M2 phenotype to the M1 phenotype and initiate a vaccine-like immune effect after primary tumor removal, which further induces an immune-favorable TME and intense immune responses for anti-CD47 antibody to simultaneously inhibit CRC distant metastasis and recurrence by immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available